 |
Generic Name: Vindesine
Brand Name(s): Eldisine®, Fildesin®
IUPAC: methyl (5S,7S,9S)-9-[(2²,3²,4²,5±,12²,19±)-3-(aminocarbonyl)-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
FDA Approval: yes
Manufacturer Link
|
Usage: Vindesine is a "semi-synthetic derivative of vinblastine," a related
microtubule inhibitor. It is administered intravenously, and is metabolized by the liver prior to excretion in the urine. Cancers for which vindesine is used include acute lymphocytic
leukemia, lung carcinomas, breast cancer, chronic myelogenous leukemia, colorectal cancer.
(1)
Mechanism: Vindesine (Eldisine®, Fildesin®), like other vinca alkaloids, binds to the tubulin building blocks used to make microtubules. Without these microtubules, dividing cells can not separate the newly replicated chromosomes, halting cell division. Aborted cell division leads to the induction of
apoptosis or cellular suicide.
(1)
Side Effects: Common side effects include hair loss, rash, nausea and vomiting, constipation, stomach cramps, jaw pain, vein
inflammation (phlebitis), decreased blood cell counts (also called bone marrow suppression or,
myelosuppression), decrease in blood platelet number (thrombocytopenia).
Print
Email Page
